Pharmafile Logo

patient expectations

Biogen Idec building

Biogen and Eisai’s Alzheimer’s drug associated with positive long-term health outcomes

A simulation model estimated lecanemab to potentially slow the rate of disease progression

- PMLiVE

Mind the gap: are digital health solutions really patient centric?

Is telemedicine beneficial for all healthcare conditions, or could this be a good time for pharma to revisit the patient journey and address any gaps?

- PMLiVE

Cytokinetics to discontinue ALS drug candidate following phase 3 trial failure

The neurodegenerative disease affects approximately 27,000 people in the US

- PMLiVE

Novo Nordisk’s weight-loss drug recommended by CHMP for adolescents

Semaglutide works by mimicking an intestinal hormone that is released after eating

- PMLiVE

Making the most of our valued talent pool

Encouraging people who are returning to work after a career break to see it as a positive experience

- PMLiVE

Origins’ Knowledge Centre

A collection of resources including webinar recordings, publications and short videos to help you be more patient focussed

Origins – The Patient Focused Specialists

- PMLiVE

Positive results for Almirall’s lebrikizumab in atopic dermatitis published in NEJM and BJD

The common inflammatory skin disease affects over 4% of adults in the EU

- PMLiVE

Bristol Myers Squibb’s Sotyktu approved by EC for plaque psoriasis

At least 100 million people worldwide are impacted by some form of psoriasis

- PMLiVE

Time to talk about health inequalities

Health inequalities are increasingly being recognised as a crucial healthcare challenge in the UK

Powering Rapid Cognitive Analysis with AI

Dr. Tom Sawyer, CFO at Cognetivity Neurosciences, discusses the benefits of AI-driven dementia detection technology for patients, health care providers, and clinical research.To find out more about Impetus: https://www.meetwithimpetus.comImpetus Digital...

Impetus Digital

- PMLiVE

AstraZeneca and Amgen’s Tezspire recommended by NICE for severe asthma

An estimated 98,000 patients with severe uncontrolled asthma may be eligible for the new treatment

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links